Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Accounts payable 413,000 395,800 327,900 351,400 364,900 375,900 363,000 323,200 303,900 126,900 198,000 173,600 195,000 127,863 127,534 127,839 155,139 107,786 101,451 100,703
Accrued expenses 2,788,600 3,219,700 2,940,000 2,795,900 2,655,300 2,907,300 2,598,100 2,326,000 2,126,700 2,264,400 2,119,500 1,720,500 1,678,600 1,584,992 1,482,556 1,532,037 1,404,971 1,703,699 1,545,407 1,258,271
Other current liabilities 363,000 357,600 279,300 648,600 527,200 316,200 391,000 377,000 311,500 218,000 238,700 286,100 268,400 201,409 226,358 284,174 317,423 192,541 151,782 179,776
Current liabilities 3,564,600 3,973,100 3,547,200 3,795,900 3,547,400 3,599,400 3,352,100 3,026,200 2,742,100 2,609,300 2,556,200 2,180,200 2,142,000 1,914,264 1,836,448 1,944,050 1,877,533 2,004,026 1,798,640 1,538,750
Long-term finance lease liabilities 112,800 114,000 346,600 361,500 376,100 390,300 404,100 417,600 430,800 442,300 482,300 495,500 509,800 513,255 524,925 530,330 539,042 546,514 522,067 532,952
Long-term operating lease liabilities 1,544,400 1,588,900 586,800 359,800 348,600 354,400 363,500 371,600 379,500 382,300 365,000 377,000 377,400 363,545 368,924 368,467 350,463
Other long-term liabilities 901,800 933,300 876,800 853,600 877,700 869,300 759,300 726,500 685,800 242,900 245,200 296,400 303,300 296,973 294,993 291,958 297,955 617,620 376,418 359,845
Long-term liabilities 2,559,000 2,636,200 1,810,200 1,574,900 1,602,400 1,614,000 1,526,900 1,515,700 1,496,100 1,067,500 1,092,500 1,168,900 1,190,500 1,173,773 1,188,842 1,190,755 1,187,460 1,164,134 898,485 892,797
Total liabilities 6,123,600 6,609,300 5,357,400 5,370,800 5,149,800 5,213,400 4,879,000 4,541,900 4,238,200 3,676,800 3,648,700 3,349,100 3,332,500 3,088,037 3,025,290 3,134,805 3,064,993 3,168,160 2,697,125 2,431,547
Preferred stock, $0.01 par value; none issued and outstanding
Common stock, $0.01 par value 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,600 2,500 2,562 2,591 2,588 2,599 2,601 2,601 2,591
Additional paid-in capital 6,672,400 6,905,700 7,101,200 7,284,700 7,449,700 7,339,600 7,369,100 7,220,200 7,386,500 7,225,500 7,100,000 6,930,200 6,880,800 7,085,950 7,640,233 7,499,161 7,894,027 7,917,375 7,943,717 7,695,905
Accumulated other comprehensive income (loss) 127,800 28,800 22,500 17,300 (14,300) (3,000) (39,800) (13,100) 800 97,600 57,500 11,300 15,900 11,537 (25,159) (33,302) (68,480) (40,982) (14,121) 13,383
Retained earnings (accumulated deficit) 9,606,800 8,693,800 7,648,400 11,242,000 10,142,400 9,173,600 8,138,300 7,222,600 6,522,800 5,703,900 4,773,400 3,962,900 3,200,800 2,430,659 1,578,731 1,511,807 858,669 254,479 (412,955) (1,250,225)
Shareholders’ equity 16,409,600 15,630,900 14,774,700 18,546,600 17,580,400 16,512,800 15,470,200 14,432,300 13,912,700 13,029,600 11,933,500 10,907,000 10,100,000 9,530,708 9,196,396 8,980,254 8,686,815 8,133,473 7,519,242 6,461,654
Total liabilities and shareholders’ equity 22,533,200 22,240,200 20,132,100 23,917,400 22,730,200 21,726,200 20,349,200 18,974,200 18,150,900 16,706,400 15,582,200 14,256,100 13,432,500 12,618,745 12,221,686 12,115,059 11,751,808 11,301,633 10,216,367 8,893,201

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Vertex Pharmaceuticals Inc. current liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc. long-term liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Vertex Pharmaceuticals Inc. total liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Vertex Pharmaceuticals Inc. shareholders’ equity increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.